NCT06301529View on ClinicalTrials.gov

The Efficacy and Tolerability of Canagliflozin in Healthy Individual

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

June 29, 2024

Study Completion Date

June 29, 2024

Conditions
Healthy Aging
Interventions
DRUG

Invokana Pill

100 mg and 150 mg doses, taken every day and every-other day, respectively.

Trial Locations (1)

48104

AgelessRx, Ann Arbor

Sponsors

Lead Sponsor

AgelessRx
All Listed Sponsors
lead

AgelessRx

INDUSTRY

NCT06301529 - The Efficacy and Tolerability of Canagliflozin in Healthy Individual | Biotech Hunter | Biotech Hunter